Hansa Biopharma AB (OSTO:HNSA)
kr 40.5 3 (8%) Market Cap: 2.66 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 77/100

Hansa Biopharma AB (publ) - Special Call Transcript

Jul 02, 2020 / 08:00AM GMT
Release Date Price: kr218.8 (+32.69%)
Operator

Ladies and gentlemen, welcome to the Hansa Biopharma AB Investor Presentation. (Operator Instructions) This call is being recorded.

I'll now hand the word over to CEO, Søren Tulstrup. Please begin.

SÃ;ren Tulstrup;publ;President;CEO
Hansa Biopharma AB

¸ - ()-&

Thank you, operator. Good morning, and welcome to the Hansa Biopharma conference call on the partnership agreement in gene therapy with Sarepta Therapeutics announced earlier today. I'm Søren Tulstrup, CEO of Hansa Biopharma. With me today, I have our Chief Scientific Officer and Chief Operating Officer, Christian Kjellman; and Chief Financial Officer, Donato Spota; as well as our Head of Investor Relations, Klaus Sindahl. Our presentation should take about 10 to 15 minutes. And after that, we'll take your questions.

Now please turn to Slide 2. Please allow me to draw your attention to our forward-looking statement, which applies to this presentation.

Please turn to Slide 3. On today's call, we'll go through

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot